SILO — Silo Pharma, Inc.

Is SILO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

Silo Pharma, Inc. (SILO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $3.07. The rating moved from Neutral to Oversold on August 13, 2026.

See all oversold Healthcare stocks →

AI analysis

Silo Pharma, Inc. (SILO) is a small, development-stage healthcare company whose near-term outlook is dominated by pipeline milestones, financing cadence, and potential partnership activity. Public information and filings are limited, producing elevated uncertainty and volatility. Sector tailwinds around biologics, CDMO/CRO demand and diagnostic interest may provide occasional positive sentiment, but execution, clinical and cash runway risks are the primary determinants of performance. Short-term market tone is mildly constructive, which could support episodic rallies, while longer-term value depends on successful clinical progress, business development outcomes, and the company’s ability to fund operations without excessive dilution.

Key factors

  • Silo Pharma, Inc. (SILO) is a small-cap, development-stage healthcare company with limited public financial disclosures and high dependency on pipeline progress.
  • Pipeline and clinical-readout sensitivity: valuation and near-term moves are likely driven by trial results, partnerships, or licensing announcements rather than fundamentals.
  • Sector thematic support from increased interest in biologics, CDMO/CRO demand and diagnostics may indirectly benefit related assets and potential collaborators.
  • Market-wide risk-on tone in the last hours supports short-term appetite for growth/biotech exposure, which may provide episodic price uplift.
  • Potential upside from business development, licensing deals, or validation by larger pharma partners could materially re-rate the stock.
  • Low liquidity/float typical of small-cap biotechs increases volatility and amplifies moves on news or social commentary.

Risks

  • Cash runway and financing risk: likely need to raise capital, with dilution risk for existing shareholders.
  • Clinical and regulatory risk: adverse or inconclusive trial results could trigger significant share price declines.
  • Execution risk: limited operational scale and dependency on third-party partners for development, manufacturing or commercialization.
  • Market microstructure: low liquidity and thin trading can cause outsized intraday moves and poor price discovery.
  • Information risk: sparse public filings and limited analyst coverage reduce transparency and increase uncertainty.
  • Macro/sector sensitivity: biotech sentiment swings, funding environments, and changes in risk appetite materially affect valuation.
  • Competition: larger pharma or better-funded biotech peers could out-innovate or capture partnership opportunities.

See today's live rating, score and targets

Members see the live hourly rating for SILO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.